Prescott Group Capital Management L.L.C. increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 66.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,000 shares of the company's stock after buying an additional 4,000 shares during the period. Prescott Group Capital Management L.L.C.'s holdings in Medpace were worth $3,322,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in MEDP. State Street Corp increased its stake in Medpace by 7.2% during the third quarter. State Street Corp now owns 752,957 shares of the company's stock valued at $251,337,000 after purchasing an additional 50,312 shares during the last quarter. Geode Capital Management LLC increased its stake in Medpace by 7.6% during the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company's stock valued at $209,885,000 after purchasing an additional 44,371 shares during the last quarter. Wellington Management Group LLP increased its stake in Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock valued at $138,612,000 after purchasing an additional 109,886 shares during the last quarter. American Capital Management Inc. increased its stake in Medpace by 2.6% during the third quarter. American Capital Management Inc. now owns 380,646 shares of the company's stock valued at $127,060,000 after purchasing an additional 9,592 shares during the last quarter. Finally, GW&K Investment Management LLC boosted its holdings in shares of Medpace by 93.9% during the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock valued at $91,516,000 after acquiring an additional 133,379 shares during the period. Institutional investors own 77.98% of the company's stock.
Wall Street Analyst Weigh In
Separately, Robert W. Baird boosted their price target on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $381.44.
View Our Latest Stock Report on Medpace
Medpace Trading Up 2.2 %
MEDP stock traded up $7.08 during trading on Friday, hitting $332.81. The company had a trading volume of 369,897 shares, compared to its average volume of 302,398. The firm has a market capitalization of $10.14 billion, a price-to-earnings ratio of 26.35, a P/E/G ratio of 3.81 and a beta of 1.47. The business has a 50 day moving average of $341.10 and a 200 day moving average of $343.29. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.
About Medpace
(
Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Featured Articles
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
